A Phase I Study of Oral CC-5013(Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer
Titel:
A Phase I Study of Oral CC-5013(Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer
Auteur:
Tohnya, Tanyifor M. Ng, Sylvia S.W. Dahut, William L. Wright, John J. Arlen, Philip M. Gulley, James L. Parker, Catherine Zeldis, Jerome Figg, William D.